Pharmala Biotech Holdings (XCNQ:MDMA) EBIT per Share : C$-0.01 (TTM As of Nov. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings EBIT per Share?

Pharmala Biotech Holdings's EBIT per Share for the three months ended in Nov. 2024 was C$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2024 was C$-0.01.

During the past 3 years, the average EBIT per Share Growth Rate was 38.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Pharmala Biotech Holdings's EBIT per Share or its related term are showing as below:

XCNQ:MDMA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 38.4 Med: 38.4 Max: 38.4
Current: 38.4

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Pharmala Biotech Holdings was 38.40% per year. The lowest was 38.40% per year. And the median was 38.40% per year.

XCNQ:MDMA's 3-Year EBIT Growth Rate is ranked better than
83.97% of 1235 companies
in the Biotechnology industry
Industry Median: 8 vs XCNQ:MDMA: 38.40

Pharmala Biotech Holdings's EBIT for the three months ended in Nov. 2024 was C$-0.44 Mil.

Pharmala Biotech Holdings EBIT per Share Historical Data

The historical data trend for Pharmala Biotech Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings EBIT per Share Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

EBIT per Share

-0.03

-0.01

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24
EBIT per Share	Get a 7-Day Free Trial									-	-	-	-	-0.01

Pharmala Biotech Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Pharmala Biotech Holdings's EBIT per Share for the fiscal year that ended in Aug. 2024 is calculated as

	EBIT per Share		(A: Aug. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.644	/	88.574
=	-0.01

Pharmala Biotech Holdings's EBIT per Share for the quarter that ended in Nov. 2024 is calculated as

	EBIT per Share		(Q: Nov. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.443	/	88.574
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01

Pharmala Biotech Holdings (XCNQ:MDMA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Pharmala Biotech Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

MDXXF:USA

Address

1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.

Executives

Fraser Macdonald	Director
Perry Tsergas	Director
Shane H.d. Morris	Director, Senior Officer
Nicholas Kadysh	Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines